Thomas J. Walsh

Prof. Dr. Thomas J. Walsh

Professor of Medicine, Pediatrics, and Microbiology & Immunology, Weill Cornell Medicine of Cornell University and Attending Physician, New York Presbyterian Hospital, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TWThomas J. Walsh
Thomas J. Walsh
MGMaria N. Gamaletsou
Maria N. Gamaletsou
MMMichael R. McGinnis
Michael R. McGinnis
RHRandall T. Hayden
Randall T. Hayden
DKDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
Early diagnosis of invasive mucormycosis is important for timely therapeutic intervention, improved survival, and reduced morbidity. Given the importance of an accurate and rapid diagnosis of invasive mucormycosis to guide the timely initiation of amphotericin B and possible surgical intervention, a coordinated multidisciplinary approach of clinical assessment, diagnostic imaging, and laboratory assessment is necessary. Laboratory assessment for mucormycosis includes the conventional methods of direct examination and culture of tissue, respiratory secretions, bronchoalveolar lavage fluid, and other fluids. However, because conventional diagnostic tools are limited in their sensitivity, advanced molecular amplification systems, antigen detection assays, proteomic profiles, and metabolite detection may complement existing approaches to improve the rate of early diagnosis of invasive mucormycosis.

10 July 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
MMMatthew McCarthy
Matthew McCarthy
ARAxel Rosengart
Axel Rosengart
ASAudrey N. Schuetz
Audrey N. Schuetz
DKDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
TWThomas J. Walsh
Thomas J. Walsh
Molds are ubiquitous in soil, water, and decaying vegetation and can cause devastating infections that are difficult to treat. This review summarizes the epidemiologic profiles, clinical characteristics, and treatment of mold infections of the central nervous system.

30 July 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MGMaria N. Gamaletsou
Maria N. Gamaletsou
DKDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
NSNikolaos V. Sipsas
Nikolaos V. Sipsas
BMBrad Moriyama
Brad Moriyama
EAElizabeth Alexander
Elizabeth Alexander
TWThomas J. Walsh
Thomas J. Walsh
Background. The epidemiology, pathogenesis, clinical manifestations, management, and outcome of Candida osteomyelitis are not well understood. Methods. Cases of Candida osteomyelitis from 1970 through 2011 were reviewed. Underlying conditions, microbiology, mechanisms of infection, clinical manifestations, antifungal therapy, and outcome were studied in 207 evaluable cases. Results. Median age was 30 years (range, ≤ 1 month to 88 years) with a >2:1 male:female ratio. Most patients (90%) were not neutropenic. Localizing pain, tenderness, and/or edema were present in 90% of patients. Mechanisms of bone infection followed a pattern of hematogenous dissemination (67%), direct inoculation (25%), and contiguous infection (9%). Coinciding with hematogenous infection, most patients had ≥2 infected bones. When analyzed by age, the most common distribution of infected sites for adults was vertebra (odds ratio [OR], 0.09; 95% confidence interval [CI], .04–.25), rib, and sternum; for pediatric patients (≤18 years) the pattern was femur (OR, 20.6; 95% CI, 8.4–48.1), humerus, then vertebra/ribs. Non-albicans Candida species caused 35% of cases. Bacteria were recovered concomitantly from 12% of cases, underscoring the need for biopsy and/or culture. Candida septic arthritis occurred concomitantly in 21%. Combined surgery and antifungal therapy were used in 48% of cases. The overall complete response rate of Candida osteomyelitis of 32% reflects the difficulty in treating this infection. Relapsed infection, possibly related to inadequate duration of therapy, occurred among 32% who ultimately achieved complete response. Conclusions. Candida osteomyelitis is being reported with increasing frequency. Localizing symptoms are usually present. Vertebrae are the most common sites in adults vs femora in children. Timely diagnosis of Candida osteomyelitis with extended courses of 6–12 months of antifungal therapy, and surgical intervention, when indicated, may improve outcome.

20 April 2017 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
DCDora E Corzo-León
Dora E Corzo-León
LCLuis D Chora-Hernández
Luis D Chora-Hernández
ARAna P Rodríguez-Zulueta
Ana P Rodríguez-Zulueta
TWThomas J. Walsh
Thomas J. Walsh
Mucormycosis is an emerging infectious disease with high rates of associated mortality and morbidity. Little is known about the characteristics of mucormycosis or entomophthoromycosis occurring in Mexico. A search strategy was performed of literature published in journals found in available databases and theses published online at Universidad Nacional Autónoma de México (UNAM) library website reporting clinical cases or clinical case series of mucormycosis and entomophthoromycosis occurring in Mexico between 1982 and 2016. Among the 418 cases identified, 72% were diabetic patients, and sinusitis accounted for 75% of the reported cases. Diabetes mellitus was not a risk factor for entomophthoromycosis. Mortality rate was 51% (125/244). Rhizopus species were the most frequent isolates (59%, 148/250). Amphotericin B deoxycholate was used in 89% of cases (204/227), while surgery and antifungal management as combined treatment was used in 90% (172/191). In diabetic individuals, this combined treatment approach was associated with a higher probability of survival (95% vs 66%, OR = 0.1, 95% CI, 0.02–0.43’ P = .002). The most common complications were associated with nephrotoxicity and prolonged hospitalization due to IV antifungal therapy. An algorithm is proposed to establish an early diagnosis of rhino-orbital cerebral (ROC) mucormycosis based on standardized identification of warning signs and symptoms and performing an early direct microbiological exam and histopathological identification through a multidisciplinary medical and surgical team. In summary, diabetes mellitus was the most common risk factor for mucormycosis in Mexico; combined antifungal therapy and surgery in ROC mucormycosis significantly improved survival.

1 October 2016 in Journal of Infection
Verified
Journal Article
Closed access
MSMichael Satlin
Michael Satlin
NCNina Cohen
Nina Cohen
KMKevin C. Ma
Kevin C. Ma
ZGZivile Gedrimaite
Zivile Gedrimaite
RSRosemary Soave
Rosemary Soave
SSSusan K. Seo
Susan K. Seo

10 June 2012 in Current Infectious Disease Reports
Verified
Journal Article
Closed access
PDF file
MGMaria N. Gamaletsou
Maria N. Gamaletsou
NSNikolaos V. Sipsas
Nikolaos V. Sipsas
EREmmanuel Roilides
Emmanuel Roilides
TWThomas J. Walsh
Thomas J. Walsh